Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
GPTRF$0.19-0.01(-5.14%)Grande Portage Resources Ltd. to Attend the 52nd Annual New Orleans Investment Conference[12:14:00 PM ET]ORCL$131.58+5.52(+4.38%)Oracle Reinvents Enterprise Computing for the AI Era with OpenAI Oracle AI World -- Oracle today announced a major new collaboration with OpenAI to redefine how the world's businesses run in the age of AI. By...[12:08:00 PM ET]ORCL$131.58+5.52(+4.38%)Oracle Brings Google TPUs to Oracle Cloud Infrastructure Oracle AI World -- Oracle and Google today announced that Google's Tensor Processing Units (TPUs) will be available through Oracle Cloud...[12:07:00 PM ET]SMP$37.43+0.15(+0.40%)Standard Motor Products, Inc. Announces Third Quarter 2026 Earnings Conference Call Standard Motor Products, Inc. (NYSE: SMP), a leading automotive parts manufacturer and distributor, is scheduled to report its earnings for the three ...[12:06:00 PM ET]SNOW$340.24+5.29(+1.58%)Oracle Expands Native AI and Data Services on OCI with Snowflake Oracle AI World -- Oracle and Snowflake (NYSE: SNOW) today announced that Snowflake AI Data Cloud will be available as a native, first-party service...[12:06:00 PM ET]ORCL$131.58+5.52(+4.38%)Oracle Advances Enterprise Security for the AI Era Oracle AI World -- Oracle today announced Oracle AI Security Mesh, powered by OpenAI. The new offering complements Oracle Cloud Infrastructure (OCI)...[12:05:00 PM ET]ORCL$131.58+5.52(+4.38%)Oracle Introduces Oracle Media Fabric Oracle AI World -- Oracle today announced Oracle Media Fabric, an integrated platform designed to help media companies, streaming providers, and...[12:04:00 PM ET]ORCL$131.58+5.52(+4.38%)Oracle Unveils New Cloud Networking Innovations for AI Oracle AI World -- Oracle today announced new capabilities in Oracle Acceleron, Oracle Cloud Infrastructure's (OCI) suite of networking and...[12:03:00 PM ET]ADT$6.89+0.00(+0.07%)ADT Secures AI Innovation with Oracle Oracle AI World -- ADT Inc. (NYSE: ADT), the trusted leader in smart home security solutions, is expanding its use of AI with Oracle AI...[12:02:00 PM ET]ORCL$131.58+5.52(+4.38%)Oracle Expands Fusion Data Intelligence with New Deep Insight Agents, Operational Analytics, and AI Capabilities Oracle AI World -- Oracle today announced new Oracle Fusion Data Intelligence capabilities that help customers uncover insights closer to the...[12:01:00 PM ET]WDFN$38.500.00(0.00%)Woodlands Financial Services Company Announces Fourth Quarter Cash Dividend[12:00:00 PM ET]CBRS$118.00+9.63(+8.89%)Cerebras and Oracle Team Up to Bring Cerebras AI Inference to Oracle Cloud Infrastructure[12:00:00 PM ET]IVZ$28.96+0.42(+1.49%)Invesco Announces Work with Anthropic to Bring its Custom Portfolio and Practice Management Capabilities to Claude Invesco Ltd. (NYSE: IVZ), a leading global asset management firm, announced today it is working with Anthropic to bring its data to support portfolio ...[12:00:00 PM ET]MSGM$4.47-0.17(-3.56%)Motorsport Games' Proprietary RaceControl Platform Powers Record Concurrent Players for Le Mans Ultimate in Biggest 24 Hours of Le Mans Online Event Yet[12:00:00 PM ET]ORCL$131.58+5.52(+4.38%)Oracle AI Data Platform Brings AI-Assisted Business Context to Enterprise AI Oracle AI World -- Oracle today announced new Oracle AI Data Platform capabilities that help customers build, deploy, and scale enterprise AI by...[12:00:00 PM ET]NVDA$218.69+2.69(+1.25%)NVIDIA and Oracle Expand NVIDIA Vera Rubin to Multi-Gigawatt Scale and Bring NVIDIA Vera CPU to Oracle Cloud Infrastructure[12:00:00 PM ET]

BEAM · NASDAQ

Beam Therapeutics Inc.

$24.91 +1.14 (+4.82%)

Company overview

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency, ocular diseases, and other liver, muscle, and central nervous system disorders.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$2.6B
Employees
393
Headquarters
Cambridge, MA
Website
beamtx.com
CEO
John Evans
Listed
February 6, 2020
P/E
-38.89
Dividend yield
4.80%

Company financials

Revenue
$164M
Gross profit
-$53.2M
Operating income
-$372M
EBITDA
-$62.8M
Net income
-$65M
EPS
-$0.64
Total assets
$1.5B
Total debt
$251M
Gross margin
-32.43%
Net margin
-39.66%
Earnings yield
-2.57%

Price chart

22.0526.2630.4734.6738.88
BEAM 1D NASDAQ O23.90H24.11L23.68C23.77-0.29 (-1.19%)Vol203.73K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
BEAMBeam Therapeutics Inc. Stock news Beam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting Tolerance MarketBeat
BEAMBeam Therapeutics Inc. Press release Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress GlobeNewswire
BEAMBeam Therapeutics Inc. Stock news Insider Selling: Beam Therapeutics (NASDAQ:BEAM) CEO Sells $589,250.00 in Stock Defense World
BEAMBeam Therapeutics Inc. Stock news Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead? The Motley Fool
BEAMBeam Therapeutics Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM PRNewsWire
BEAMBeam Therapeutics Inc. Stock news Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse Benzinga
BEAMBeam Therapeutics Inc. Press release Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress GlobeNewswire
BEAMBeam Therapeutics Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM ACCESS Newswire
BEAMBeam Therapeutics Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM ACCESS Newswire
BEAMBeam Therapeutics Inc. Stock news Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress Seeking Alpha
ACHC Stock news Squeeze Watch: 10 Stocks With Over 33% Short Interest Benzinga
BEAMBeam Therapeutics Inc. Stock news CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon 24/7 Wall Street
BEAMBeam Therapeutics Inc. Legal BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law Business Wire
BEAMBeam Therapeutics Inc. Legal BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law GuruFocus
BEAMBeam Therapeutics Inc. Stock news These 10 Stocks Are Squeeze Candidates Waiting to Happen Benzinga
BEAMBeam Therapeutics Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM GuruFocus
BEAMBeam Therapeutics Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM PR Newswire
BEAMBeam Therapeutics Inc. Stock news Beam Therapeutics Inc. (BEAM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Seeking Alpha
BEAMBeam Therapeutics Inc. Stock news Traders Buy Large Volume of Beam Therapeutics Call Options (NASDAQ:BEAM) Defense World
BEAMBeam Therapeutics Inc. Stock news 3 Promising Genomics Stocks in the Spotlight in 2026 Zacks Investment Research
See more
FAQ

Questions about Beam Therapeutics Inc.

What does Beam Therapeutics Inc. do?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency, ocular diseases, and other liver, muscle, and central nervous system disorders.
What is BEAM's market cap?
Beam Therapeutics Inc. (BEAM) is a listed stock with a live quote. The latest market cap on this page is $2.6B.
Where is Beam Therapeutics Inc. headquartered?
Beam Therapeutics Inc. is headquartered in Cambridge, MA.
How do I get BEAM news from the API?
Call GET /v1/news?tickers=BEAM. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does BEAM news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for BEAM, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the BEAM price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs